Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04952766 | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults(EREVA) | completed | Phase 4 | 196 | Centre Hospitalier Régional d'OrléansOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | recruiting | Phase 4 | 15 | University Health Network, TorontoOTHER | 1 | Dec 10, 2025 |
| clinicaltrials |
| NCT07270835 | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma | recruiting | Phase 4 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07264894 | ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial | not yet recruiting | Phase 4 | 30 | Zhengzhou UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03829371 | STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | active not recruiting | Phase 4 | 450 | University of Turin, ItalyOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05687032 | A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 4 | 44 | PfizerINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05511428 | Home Based Daratumumab Administration for Patients With Multiple Myeloma | completed | Phase 4 | 20 | Thomas Jefferson UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07025005 | Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)(VRd MM Fibrate) | recruiting | Phase 4 | 44 | Tanta UniversityOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | completed | Phase 4 | 50 | TakedaINDUSTRY | 10 | Sep 19, 2025 | clinicaltrials |
| NCT05442554 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma | completed | Phase 4 | 10 | TakedaINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07154537 | Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) | active not recruiting | Phase 4 | 101 | National Taiwan University HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07016165 | Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies | recruiting | Phase 4 | 120 | Gadjah Mada UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07105319 | Ropeginterferon for Treatment Free Remission(ROPEG) | completed | Phase 4 | 65 | Dong-Wook KimOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07046182 | Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight | active not recruiting | Phase 4 | 34 | Zhengzhou UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | recruiting | Phase 4 | 59 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03190330 | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion | completed | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT04042376 | A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) | completed | Phase 4 | 17 | Janssen Research & Development, LLCINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT06956092 | Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma(Glofitamab) | not yet recruiting | Phase 4 | 40 | Zhengzhou UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05071482 | Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL | terminated | Phase 4 | 39 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05555329 | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study(POMAlternative) | completed | Phase 4 | 12 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03500133 | Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.(LHGALOP2017) | recruiting | Phase 4 | 500 | Hospital JP GarrahanOTHER_GOV | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06918054 | Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia | recruiting | Phase 4 | 42 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06918080 | Hepatoprotective Measures for Children at High Risk of NAFLD | active not recruiting | Phase 4 | 200 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03844360 | Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease | recruiting | Phase 4 | 1,500 | Wei ZhaoOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05108805 | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | completed | Phase 4 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT04080531 | Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders | completed | Phase 4 | 165 | Emory UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05944783 | Bioequivalence Studies of Dasatinib 100 Mg(BE-Dasatinib) | not yet recruiting | Phase 4 | 46 | Centro de Atencion e Investigacion MedicaNETWORK | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01804166 | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | completed | Phase 4 | 1 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | completed | Phase 4 | 150 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06665737 | Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients(G-CSF in NHL) | not yet recruiting | Phase 4 | 126 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06761911 | BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma | not yet recruiting | Phase 4 | 100 | Xiuhua SunOTHER | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06711679 | Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia | enrolling by invitation | Phase 4 | 180 | Yilin ZhaoOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05806580 | Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 4 | 8 | Ruijin HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06609304 | Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma(axi-cel) | recruiting | Phase 4 | 20 | Zhengzhou UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT02926586 | Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML | completed | Phase 4 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06582186 | Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm(VORIPRECI) | not yet recruiting | Phase 4 | 30 | University Hospital, GrenobleOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06571825 | RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR | recruiting | Phase 4 | 118 | He HuangOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT04217967 | Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | completed | Phase 4 | 211 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06425276 | Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation | completed | Phase 4 | 67 | CASI Pharmaceuticals (China) Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT06410833 | Belimumab After Rituximab in Resistant Primary Juvenile SS(BRRPJS) | recruiting | Phase 4 | 15 | Peking Union Medical College HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT00733538 | Stage I Multiple Myeloma Treatment(IFM-01-04) | completed | Phase 4 | 89 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03817853 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 7 | Apr 4, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT01088750 | Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma(EuroNetLP1) | completed | Phase 4 | 225 | Christine Mauz-KörholzOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03677596 | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | completed | Phase 4 | 102 | PfizerINDUSTRY | 8 | Nov 22, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT06026995 | Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells | unknown | Phase 4 | 174 | Chongqing University Cancer HospitalOTHER | 1 | Sep 7, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Dec 23, 2025source: clinicaltrials